BRIEF-Ziopharm says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma
January 11, 2017 at 11:02 AM EST
* Ziopharm Oncology says end of face-to-face meeting with FDA in early Q1 2017 with respect to recurrent Glioblastoma - Sec Filing